MRNA therapeutic compositions

Smart overview of the Invention

Multimodal mRNA-based immunotherapies are designed to deliver both antigens and immunomodulators in a single therapeutic approach. These innovative compositions aim to treat cancers associated with human papillomavirus (HPV) by addressing both the disease and its underlying cause, which is persistent HPV infection. Related formulations, administration methods, and kits are also included in the technology.

Importance of HPV in Cancer

HPV is a significant contributor to various cancers, particularly cervical cancer, which is linked to high-risk types like HPV16 and HPV18. Current treatments primarily focus on removing abnormal tissues but often fail to eliminate the underlying HPV infection. As a result, there is a substantial risk of recurrence and progression to invasive cancer, highlighting the need for effective non-surgical therapeutic options.

Potential of mRNA-based Therapies

The described mRNA therapies include isolated polypeptides and polynucleotides that encode specific proteins, including a membrane-stabilized LIGHT. The technology details the structure of these mRNAs, including their 5' and 3' untranslated regions (UTRs), which are critical for stability and translation efficiency. Modifications to the nucleobase-sugar-internucleoside linkages enhance the therapeutic potential of these mRNAs.

Composition Details

The compositions may also include additional mRNA sequences that encode checkpoint inhibitors or pro-inflammatory agents such as interleukin-12. These components work together to stimulate an immune response against cancer cells while mitigating immunosuppression, ultimately improving treatment outcomes for patients with HPV-related cancers.

Conclusion and Future Directions

With over half a million new cervical cancer cases annually worldwide, innovative treatments are desperately needed. The proposed mRNA-based immunotherapies represent a promising avenue for addressing this unmet medical need by potentially enhancing tumor-specific T cell responses and improving patient survival rates. Continued research and development in this area may lead to significant advancements in the management of HPV-associated cancers.